EORTC is all about science and progress in cancer care
More than 50 years ago, visionary leaders in cancer medicine realised that patient management cannot advance without a solid understanding of the disease and its biology, vigorous testing of novel treatments, and cross-disciplinary collaboration beyond state borders. This is how EORTC approaches cancer clinical research.
We look for impactful new solutions, placing patients at the centre of our programmes
In a rapidly-changing healthcare environment, fresh approaches such as precision medicine and immunotherapy are dominating drug development and therapeutic strategies. Traditional clinical research is transforming to new pathways and mechanisms. Modern challenges in research come from our understanding of tumour heterogeneity and escape mechanisms, the increasing role of biomarkers, and new types of end-points and data.
As oncology rapidly evolves into an era of precision medicine, EORTC’s strategy encompasses the latest developments:
- The integration of pharmacology, molecular biology, tumour immunology and imaging, as well as transversal problem-solving beyond organ-based medicine.
- Open platforms for molecular tumour characterisation to help access sub-groups of molecularly-defined patients in an efficient way.
- Analytical and clinical validation of biomarker and related assays.
- Novel tools and imaging methods to evaluate the effects of treatment quickly and thoroughly.
- Constructive lobbying for a regulatory environment conducive to patient-friendly innovation.
- Partnerships and collaborations with industry, patient advocacy groups, and professional societies to build new research models and optimise resources.
- Collaborative approaches with patient registries to evaluate the “real-world” impact of clinical research and true benefits of treatments, in the context of people’s actual access to drugs and optimising their use outside a study.
- Following patients beyond their disease, through integrative and original research programmes addressing long-term outcomes and social impact.